Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2014

Open Access 01-12-2014 | Poster presentation

PB.36. Imaging in gynaecomastia: audit of referral and imaging practise to establish referral guidelines

Authors: K Bonam, A Leaver, S Sharma

Published in: Breast Cancer Research | Special Issue 1/2014

Login to get access

Excerpt

There is variation in the literature and between breast units in use of imaging in clinically suspected gynaecomastia. Our study aim was to audit referral and imaging in our breast unit, formulating guidelines and standardising practise. …
Metadata
Title
PB.36. Imaging in gynaecomastia: audit of referral and imaging practise to establish referral guidelines
Authors
K Bonam
A Leaver
S Sharma
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2014
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3718

Other articles of this Special Issue 1/2014

Breast Cancer Research 1/2014 Go to the issue

Poster presentation

PB.2. Axillary node ultrasound in breast cancer: which threshold for 'diffuse cortical thickening' predicts node metastasis?

Poster presentation

PB.30. Apparent diffusion coefficient and fractional anisotropy values as biomarkers for treatment response in breast cancer

Poster presentation

PB.16. Breast screening mammograms: recall or not to recall. What is the golden ratio?

Poster presentation

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

Poster presentation

PB.29. Retrospective correlation between MRI and histopathology in preoperative assessment of invasive breast carcinoma

Poster presentation

PB.26. MRI-guided breast biopsy in Leeds: 12 years' experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits